Preoperative normalization of cortisol levels in cushing's disease after medical treatment: Consequences for somatostatin and dopamine receptor subtype expression and in vitro response to somatostatin analogs and dopamine agonists

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 12, 2013, Pages

  Van Der Pas, R ^a   Feelders, R A ^a   Gatto, F ^a   De Bruin, C ^a   Pereira, A M ^b   Van Koetsveld, P M ^a   Sprij Mooij, D M ^a   Waaijers, A M ^a   Dogan, F ^a   Schulz, S ^c   Kros, J M ^a   Lamberts, S W J ^a   Hofland, L J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CABERGOLINE; CORTICOTROPIN; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; HYDROCORTISONE; MESSENGER RNA; OCTREOTIDE; PASIREOTIDE; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 5;

ACTH SECRETING ADENOMA; ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOTROPIN RELEASE; CUSHING DISEASE; DISEASE ASSOCIATION; DRUG EFFECT; DRUG POTENCY; DRUG RESPONSE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MALE; MIDDLE AGED; MOLECULAR DYNAMICS; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; URINE LEVEL; YOUNG ADULT;

ACTH-SECRETING PITUITARY ADENOMA; ADOLESCENT; ADRENAL GLANDS; ADULT; AGED; ANTINEOPLASTIC AGENTS; DOPAMINE AGONISTS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; HYDROCORTISONE; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PITUITARY ACTH HYPERSECRETION; PITUITARY GLAND; PROTEIN ISOFORMS; RECEPTORS, DOPAMINE D2; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN; TUMOR CELLS, CULTURED; YOUNG ADULT;

EID: 84889789663     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-1987     Document Type: Article

References (48)

1. Boscaro M, Barzon L, Fallo F, Sonino N. Cushing's syndrome. Lancet. 2001;357:783-791.
2. Atkinson AB, Kennedy A, Wiggam MI, McCance DR, Sheridan B. Long-term remission rates after pituitary surgery for Cushing's disease: the need for long-term surveillance. Clin Endocrinol (Oxf). 2005;63:549-559.
3. Biller BM, Grossman AB, Stewart PM, et al. Treatment of adrenocorticotropin- dependent Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab. 2008;93:2454-2462.
4. de Bruin C, Pereira AM, Feelders RA, et al. Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas. J Clin Endocrinol Metab. 2009;94:1118-1124.
5. Batista DL, Zhang X, Gejman R, et al. The effects ofSOM230on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. J Clin Endocrinol Metab. 2006;91:4482-4488.
6. Pivonello R, Ferone D, de Herder WW, et al. Dopamine receptor expression and function in corticotroph pituitary tumors. J Clin Endocrinol Metab. 2004;89:2452-2462.
7. Boscaro M, Ludlam WH, Atkinson B, et al. Treatment of pituitarydependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase 2 trial. J Clin Endocrinol Metab. 2009;94:115-122.
8. Feelders RA, de Bruin C, Pereira AM, et al. Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease. N Engl J Med. 2010;362:1846-1848.
9. Pivonello R, De Martino MC, Cappabianca P, et al. The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab. 2009;94:223-230.
10. Hofland LJ, Lamberts SW. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev. 2003;24:28-47.
11. Schonbrunn A. Glucocorticoids down-regulate somatostatin receptors on pituitary cells in culture. Endocrinology. 1982;110:1147- 1154.
12. Stalla GK, Brockmeier SJ, Renner U, et al. Octreotide exerts different effects in vivo and in vitro in Cushing's disease. Eur J Endocrinol. 1994;130:125-131.
13. van der Hoek J, Waaijers M, van Koetsveld PM, et al. Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells. Am J Physiol. 2005;289:E278-E287.
14. de Bruin C, Feelders RA, Waaijers AM, et al. Differential regulation of human dopamine D2 and somatostatin receptor subtype expression by glucocorticoids in vitro. J Mol Endocrinol. 2009;42:47-56.
15. Lamberts SW, Uitterlinden P, Klijn JM. The effect of the long-acting somatostatin analogue SMS 201-995 on ACTH secretion in Nelson's syndrome and Cushing's disease. Acta Endocrinol. 1989;120: 760-766.
16. Tyrrell JB, Lorenzi M, Gerich JE, Forsham PH. Inhibition by somatostatin of ACTH secretion in Nelson's syndrome. J Clin Endocrinol Metab. 1975;40:1125-1127
17. Fehm HL, Voigt KH, Lang R, Beinert KE, Raptis S, Pfeiffer EF. Somatostatin: a potent inhibitor of ACTH-hypersecretion in adrenal insufficiency. Klin Wochenschr. 1976;54:173-175.
18. Hofland LJ, Feelders RA, de Herder WW, Lamberts SW. Pituitary tumours: the sst/D2 receptors as molecular targets. Mol Cell Endocrinol. 2010;326:89-98.
19. Hofland LJ, van der Hoek J, van Koetsveld PM, et al. The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro. J Clin Endocrinol Metab. 2004;89:1577-1585.
20. Fischer T, Doll C, Jacobs S, Kolodziej A, Stumm R, Schulz S. Reassessment of sst2 somatostatin receptor expression in human normal and neoplastic tissues using the novel rabbit monoclonal antibody UMB-1. J Clin Endocrinol Metab. 2008;93:4519-4524.
21. Gatto F, Feelders RA, van der Pas R, et al. Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly. J Clin Endocrinol Metab. 2013;98:E66-E71.
22. Körner M, Waser B, Schonbrunn A, Perren A, Reubi JC. Somatostatin receptor subtype 2A immunohistochemistry using a new monoclonal antibody selects tumors suitable for in vivo somatostatin receptor targeting. Am J Surg Pathol. 2012;36:242-252.
23. Lupp A, Hunder A, Petrich A, Nagel F, Doll C, Schulz S. Reassessment of sst(5) somatostatin receptor expression in normal and neoplastic human tissues using the novel rabbit monoclonal antibody UMB-4. Neuroendocrinology. 2011;94:255-264.
24. Remmele W, Stegner HE. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue [in German]. Pathologe. 1987;8:138-140.
25. Oosterom R, Blaauw G, Singh R, Verleun T, LambertsSW.Isolation of large numbers of dispersed human pituitary adenoma cells obtained by aspiration. J Clin Invest. 1984;7:307-311.
26. I-Tyr3]octreotide by mouse and human pituitary tumor cells: increase by unlabeled octreotide. Endocrinology. 1995; 136:3698-3706.
27. Croughs RJ, Docter R, de Jong FH. Comparison of oral and intravenous dexamethasone suppression tests in the differential diagnosis of Cushing's syndrome. Acta Endocrinol. 1973;72:54-62.
28. Godbout A, Manavela M, Danilowicz K, Beauregard H, Bruno OD, Lacroix A. Cabergoline monotherapy in the long-term treatment of Cushing's disease. Eur J Endocrinol. 2010;163:709-716.
29. Vilar L, Naves LA, Azevedo MF, et al. Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing's disease. Pituitary. 2010;13:123-129.
30. Colao A, Petersenn S, Newell-Price J, et al. A 12-month phase 3 study of pasireotide in Cushing's disease. N Engl J Med. 2012;366:914-924.
31. Xu Y, Berelowitz M, Bruno JF. Dexamethasone regulates somatostatin receptor subtype messenger ribonucleic acid expression in rat pituitary GH4C1 cells. Endocrinology. 1995;136:5070-5075.
32. Park S, Kamegai J, Kineman RD. Role of glucocorticoids in the regulation of pituitary somatostatin receptor subtype (sst1-sst5) mRNA levels: evidence for direct and somatostatin-mediated effects. Neuroendocrinology. 2003;78:163-175.
33. Ambrosi B, Bochicchio D, Fadin C, Colombo P, Faglia G. Failure of somatostatin and octreotide to acutely affect the hypothalamic-pituitary- adrenal function in patients with corticotropin hypersecretion. J Clin Invest. 1990;13:257-261.
34. Ben-Shlomo A, Schmid H, Wawrowsky K, et al. Differential ligandmediated pituitary somatostatin receptor subtype signaling: implications for corticotroph tumor therapy. J Clin Endocrinol Metab. 2009;94:4342-4350.
35. Vignati F, Loli P. Additive effect of ketoconazole and octreotide in the treatment of severe adrenocorticotropin-dependent hypercortisolism. J Clin Endocrinol Metab. 1996;81:2885-2890.
36. Hofland LJ. Somatostatin and somatostatin receptors in Cushing's disease. Mol Cell Endocrinol. 2008;286:199-205.
37. de Bruin C, Hofland LJ, Nieman LK, et al. Mifepristone effects on tumor somatostatin receptor expression in two patients with Cushing's syndrome due to ectopic adrenocorticotropin secretion. J Clin Endocrinol Metab. 2012;97:455-462.
38. Takei M, Suzuki M, Kajiya H, et al. Immunohistochemical detection of somatostatin receptor (SSTR) subtypes 2A and 5 in pituitary adenoma from acromegalic patients: good correlation with preoperative response to octreotide. Endocr Pathol. 2007;18:208-216.
39. Fougner SL, Borota OC, Berg JP, Hald JK, Ramm-Pettersen J, Bollerslev J. The clinical response to somatostatin analogues in acromegaly correlates to the somatostatin receptor subtype 2a protein expression of the adenoma. Clin Endocrinol (Oxf). 2008;68:458-465.
40. Ferone D, de Herder WW, Pivonello R, et al. Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy. J Clin Endocrinol Metab. 2008;93:1412-1417.
41. Plöckinger U, Albrecht S, Mawrin C, et al. Selective loss of somatostatin receptor 2 in octreotide-resistant growth hormone-secreting adenomas. J Clin Endocrinol Metab. 2008;93:1203-1210.
42. Hofland LJ, van der Hoek J, Feelders R, et al. The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur J Endocrinol. 2005;152:645-654.
43. Ben-Shlomo A, Wawrowsky KA, Proekt I, et al. Somatostatin receptor type 5 modulates somatostatin receptor type 2 regulation of adrenocorticotropin secretion. J Biol Chem. 2005;280:24011-24021.
44. Ben-Shlomo A, Melmed S. Pituitary somatostatin receptor signaling. Trends Endocrinol Metab. 2010;21:123-133.
45. Reubi JC, Waser B, Cescato R, Gloor B, Stettler C, Christ E. Internalized somatostatin receptor subtype 2 in neuroendocrine tumors of octreotide-treated patients. J Clin Endocrinol Metab. 2010;95: 2343-2350.
46. Lesche S, Lehmann D, Nagel F, Schmid HA, Schulz S. Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro. J Clin Endocrinol Metab. 2009; 94:654-661.
47. Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC, Patel YC. Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science. 2000;288:154-157.
48. Saveanu A, Gunz G, Guillen S, Dufour H, Culler MD, Jaquet P. Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas. Neuroendocrinology. 2006;83:258-263.